WARNER-LAMBERT NEURONTIN USE IN NON-EPILEPTIC CONDITIONS UNDER STUDY; ANTIDIABETIC TROGLITAZONE IN NIDDK TYPE II PREVENTION TRIAL, NDA SLATED FOR SUMMER
Executive Summary
One-quarter of the use of Warner-Lambert's anti-epileptic Neurontin (gabapentin) is for "conditions other than epilepsy," Parke-Davis Chairman Ronald Cresswell, PhD, told securities analysts April 11 in New York City. "We are aggressively investigating the effects of Neurontin on psychological conditions such as bipolar disorders and social phobias," Cresswell said. "We have begun multi-center pain studies in neuropathic pain and in post-herpetic neuralgia," he added. Sales of Neurontin in 1995 totaled $102 mil.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth